Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report

Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and its corresponding ligand PD-L1 are being increasingly used for a wide variety of cancers, including refractory sarcomas. Autoimmune hepatitis is a known side effect of ICIs, and is typically managed with broad, non-spec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zarrabi, Maiah, Hamilton, Camille, French, Samuel W., Federman, Noah, Nowicki, Theodore S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262312/
https://www.ncbi.nlm.nih.gov/pubmed/37325672
http://dx.doi.org/10.3389/fimmu.2023.1156746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262312/
https://www.ncbi.nlm.nih.gov/pubmed/37325672
http://dx.doi.org/10.3389/fimmu.2023.1156746

Ejemplares similares